Physician profile
Nancy Kang
NPI 1447570494
$7,705.71
in general payments reported to CMS, 2019-2025
37 companies · $2,198 in 2025
The $2,198 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $245 · 2021: $568 · 2022: $1,174 · 2023: $1,605 · 2024: $1,535 · 2025: $2,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,225 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,224.84 |
| Education | $113.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,798.57 | 2019-2025 | |
| Janssen Biotech, INC. | $1,603.57 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $958.05 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.45 | 2019-2023 | Trulance, Xifaxan |
| Celgene Corporation | $293.68 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $239.84 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $239.78 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $191.75 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $188.76 | 2020-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $171.23 | 2025 | Rezdiffra |
| Pfizer INC. | $164.40 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $157.28 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $142.22 | 2024-2025 | Omvoh |
| Genzyme Corporation | $117.02 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $114.38 | 2021-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.